U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07205822) titled 'A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer' on Sept. 11.
Brief Summary: A study to assess the efficacy and safety of Dato-DXd in the pre-chemotherapy setting for patients with metastatic HR-positive, HER2 IHC 0 breast cancer.
Study Start Date: Sept. 30
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
DRUG: Dato-DXd
All participants will receive Dato-DXd (6 mg/kg IV on Day 1, Q3W; up to a maximum of 540 mg Q3W for participants >= 90 kg) until investigator-defined disease progression according to RECIST 1.1 or until unacceptable toxicity, withdrawal of con...